Substance / Medication

Fleroxacin

Overview

Active Ingredient
fleroxacin
RxNorm CUI
42322

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Protective effect of fleroxacin against the nephrotoxicity of isepamicin in rats.
Yazaki Tomoko, Yoshiyama Yuji, Wong Paul et al. · Biol Pharm Bull · 2002
PMID: 11995935Observational
Photodegradation of fleroxacin by g-CN/PPy/Ag and HPLC-MS/MS analysis of degradation pathways.
Ma Lei, Yang Lin, Li Laijun et al. · RSC Adv · 2023
PMID: 37077267ReviewFull text (PMC)
Ag@NbCTMXene composites for efficient photocatalytic degradation of norfloxacin and fleroxacin antibiotics.
Munir Javeria, Sajid Imran Haider, Irfan Syed et al. · RSC Adv · 2025
PMID: 40686642OtherFull text (PMC)
Metal(II) Complexes of the Fluoroquinolone Fleroxacin: Synthesis, Characterization and Biological Profile.
Kostelidou Alexandra, Perdih Franc, Kljun Jakob et al. · Pharmaceutics · 2022
PMID: 35631484OtherFull text (PMC)
Effects of environmental factors on the fleroxacin photodegradation with the identification of reaction pathways.
Huang Ruisi, Cao Hongyu, Huang Ting et al. · Chemosphere · 2022
PMID: 36113649Other
Comparison of fleroxacin oxidation by chlorine and chlorine dioxide: Kinetics, mechanism and halogenated DBPs formation.
He Guilin, Zhang Tuqiao, Li Yunfei et al. · Chemosphere · 2022
PMID: 34293556Other
Establishment of an immunological detection method of fleroxacin by fluorescence-linked immunosorbent assay.
Liu Yankai, Wang Yajie, Zhou Jingming et al. · Food Addit Contam Part A Chem Anal Control Expo Risk Assess · 2021
PMID: 33667148Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Fleroxacin (substance)
SNOMED CT
96085003
UMLS CUI
C0085161
RxNorm CUI
42322

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.